Tirzepatide

Specifications：5/10/15/20/30/40/50/60mg/vial

10vials/kit

CAS NO.：2023788-19-2

Packaging: Support packaging customization

Minimum order quantity: 10 pieces

WhatsApp/Tel:+8618332173750

Email:admin@hb-mh.cn

Description

Tirzepatide is a new dual-receptor channel agonist for glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory peptide). Administer once a week. Both GLP-1 and GIP are incretins, polypeptides secreted by the human gastrointestinal mucosa. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thus producing a hypoglycemic effect and delaying gastric excretion. Empty and suppress appetite, thereby controlling weight; while the latter has the functions of inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric motility and emptying, and can supplement the GLP-1 receptor agonist effect. Tirzepatide combines two insulinotropic effects into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

Payment and Delivery